>
Switch to:

Intec Parent PE Ratio without NRI

: At Loss (As of Today)
View and export this data going back to 1996. Start your Free Trial

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2021-10-17), Intec Parent's share price is $9.63. Intec Parent's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 was $-14.95. Therefore, Intec Parent's PE Ratio without NRI for today is At Loss.

Intec Parent's EPS without NRI for the three months ended in Mar. 2021 was $-3.84. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 was $-14.95.

As of today (2021-10-17), Intec Parent's share price is $9.63. Intec Parent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $. Therefore, Intec Parent's PE Ratio for today is N/A.

Intec Parent's EPS (Diluted)for the three months ended in Mar. 2021 was $-3.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00.

Intec Parent's EPS (Basic) for the three months ended in Mar. 2021 was $-3.84. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2021 was $-14.56.


Intec Parent PE Ratio without NRI Historical Data

The historical data trend for Intec Parent's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PE Ratio without NRI
Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
PE Ratio without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison

For the Biotechnology subindustry, Intec Parent's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Intec Parent PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, Intec Parent's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Intec Parent's PE Ratio without NRI falls into.



Intec Parent PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Intec Parent's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=9.63/-14.945
=-0.64(At Loss)

Intec Parent's Share Price of today is $9.63.
Intec Parent's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.95.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Intec Parent  (NAS:NTEC) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Intec Parent PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Intec Parent's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent Business Description

Intec Parent logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Linscott Walt Addison officer: Chief Business Officer 1860 MONTREAL ROAD TUCKER GA 30084
Sassi Nir officer: Chief Financial Officer 3 ELUL STREET, APT. 6 MODIIN L3 7176397
Navon Nadav officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Maddaluna Anthony J director PFIZER INC. ATTN CORPORATE SECRETARY 235 RAST 42ND STREET NEW YORK NY 10017
Hayes William B director 231 MAPLE AVENUE BURLINGTON NC 27215
Pomerantz Roger director 711 HARVEST HILL ROAD CHALFONT PA 18914
Karah Hila director 9 HALAMISH STREET CAESAREA INDUSTRIAL PARK CAESAREA L3 38900
Kozarich John W director 10275 SCIENCE CENTER DR SAN DIEGO CA 92121
Meckler Jeffrey A director, officer: Chief Executive Officer 740 BROADWAY 9TH FLOOR NEW YORK NY 10003
Gendreau R Michael officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Oren Dan 10 percent owner 1 DEXCEL STREET OR AKIVA L3 30600000
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET OR AKIVA L3 3060000
Bianco Gil director 7 HAORANIM STREET BAZRA L3 60944
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)